No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Tuesday, October 28, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Markets

Medtronic makes two key additions to its board. How activist Elliott can build shareholder value

by TheAdviserMagazine
2 months ago
in Markets
Reading Time: 5 mins read
A A
Medtronic makes two key additions to its board. How activist Elliott can build shareholder value
Share on FacebookShare on TwitterShare on LInkedIn


Michael Siluk | Education Images | Universal Images Group | Getty Images

Company: Medtronic PLC (MDT)

Business: Medtronic PLC is an Ireland-based company, which provides health-care technology solutions. The company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

Stock Market Value: $118.78B ($92.71 per share)

Stock Chart IconStock chart icon

Medtronic shares in 2025

Activist: Elliott Investment Management

Ownership: n/a

Average Cost: n/a

Activist Commentary: Elliott is a very successful and astute activist investor. The firm’s team includes analysts from leading tech private equity firms, engineers, operating partners – former technology CEOs and COOs. When evaluating an investment, the firm also hires specialty and general management consultants, expert cost analysts and industry specialists. Elliott often watches companies for many years before investing and has an extensive stable of impressive board candidates. The firm has historically focused on strategic activism in the technology sector and has been very successful with that strategy. However, over the past several years its activism group has grown, and Elliott has been doing a lot more governance-oriented activism and creating value from a board level at a much larger breadth of companies.

What’s happening

On Aug. 19, Medtronic PLC announced the appointment of John Groetelaars (former interim CEO of Dentsply Sirona and former president and CEO of Hillrom) and Bill Jellison (former vice president, CFO of Stryker) to the board following engagement with Elliott. Further, the board announced the formation of the Growth Committee and the Operating Committee. Jellison will serve on both, while Groetelaars will join the Growth committee.

Behind the scenes

Medtronic is the largest medtech company in the world by revenue, with a history of medtech innovation and market leadership dating back to the 1940s. While its cardiology segment remains its legacy core business (37% of revenue), Medtronic is now a diversified operator, with its other segments including Neuroscience (29%), Medical Surgical (25% and largely built from their acquisition of Covidien, which closed in 2015) and Other (9%, primarily diabetes treatment). Despite this positioning as a one-stop shop for medical devices, Medtronic’s stock price has stagnated – appreciating just 15% over the past decade and down 8% in the last five years.

This stock performance underscores long-term investor frustration in Medtronic’s growth profile. Investors have been long waiting for a growth inflection due to the company’s attractive end markets and scale, but Medtronic has been delivering underwhelming mid-single digit revenue growth for the past 10 years. Many have speculated that Medtronic’s growth has disappointed due to its strategy of diversification. While Medtech peers like Boston Scientific and Intuitive Surgical are pursuing depth rather than diversification, executing tuck-in merger and acquisitions, and building scale in focused markets, Medtronic has sat on the sidelines since the Covidien acquisition, leaving it with a larger – but slower growing revenue base than peers.

However, for the first time in many years management is sending a message to the market that it not only acknowledges this issue, but it’s doing something about it. That message comes in the form of establishing a Growth Committee and adding as a member newly appointed director Bill Jellison (former vice president and CFO of Stryker). Notably, these actions were taken following engagement by Elliott. The Growth Committee is oriented towards portfolio management, including finding tuck-in M&A opportunities to supplement organic growth, allocating research and development more effectively, and reviewing its existing portfolio of businesses for inefficiencies to pursue future asset sales. Jellison will be a value-added director to that end. In addition, Elliott has shown that even without a board seat for an Elliott principal it can be a valuable active shareholder, particularly with evaluating and executing M&A opportunities.

Medtech has also seen margin challenges in recent years and management is also addressing that by forming an Operating Committee. This committee is focused on creating room in the P&L and gross margin expansion. As is the case with most MedTech businesses, Medtronic has been under a lot of bottom-line pressure since the Covid-19 pandemic. However, while peers have generally experienced 100 to 200 basis points of margin pressure, Medtronic’s gross margins (now around 65%) have eroded approximately 500 bps. This is another area where we have seen Elliott assist portfolio companies as an active shareholder.

While these two committees are new, they will be able to start with a little momentum. Medtronic announced in May that it will be spinning off its diabetes business within the next 15 months, which should help the company focus on its core businesses. There are also two product developments that could meaningfully contribute to long-term growth: (i) PulseSelect, a pulse field ablation system used to treat atrial fibrillation, launched in the U.S. in 2024 and has grown rapidly over the course of this year; and (ii) Symplicity Spyral, a renal denervation product used for the treatment of hypertension, recently received a favorable reimbursement decision from the Centers for Medicare & Medicaid Services that’s being finalized in October, which should significantly increase access and adoption of the product. While these product developments are certainly reasons to be optimistic, more important to shareholders like Elliott is a professional and sophisticated process, and with these operational and governance changes, shareholders should be confident that the company finally has a process that can deliver long-term growth. To paraphrase from the book “Built to Last: Successful Habits of Visionary Companies,” it is the difference between being a time teller and a clock builder. The most successful and enduring companies have been clock builders.

Elliott is one of today’s most prolific activist investors, and it has already successfully completed the activist phase of this engagement. Now is the time for phase two: a turnaround of the business. Elliott has helped add two directors to the board who are purpose-built for this situation. Both Jellison and Groetelaars have extensive medtech experience, with Jellison having served on the boards of two other medtech companies as the result of activist engagement – Masimo for Politan Capital and Anika Therapeutics for Caligan Partners. What makes this engagement unique is that Elliott did not enter into any formal agreement with Medtronic, signaling that management did not see it as necessary and that Elliott is supportive of its efforts. While presently the stage is set for a long-term mutually beneficial relationship between the two parties, Elliott has put itself in position to have unique flexibility should things not go as planned, but we do not expect that they will have to rely on that contingency.

Ken Squire is the founder and president of 13D Monitor, an institutional research service on shareholder activism, and the founder and portfolio manager of the 13D Activist Fund, a mutual fund that invests in a portfolio of activist 13D investments.



Source link

Tags: activistadditionsboardBuildElliottkeyMedtronicshareholder
ShareTweetShare
Previous Post

Recession specials could be the latest sign of deteriorating consumer sentiment

Next Post

Hot Stocks: KW 34 / 2025 – Biotech-Aktien setzen ein Ausrufzeichen!

Related Posts

edit post
The Best Streaming Services — With Live TV — Ranked

The Best Streaming Services — With Live TV — Ranked

by TheAdviserMagazine
October 27, 2025
0

ESB Professional / Shutterstock.comWhich live TV streaming services truly are a better alternative to cable? Does one rise above the...

edit post
I’m a Professional Thrifter. Here’s What I Do Differently When Shopping at Goodwill.

I’m a Professional Thrifter. Here’s What I Do Differently When Shopping at Goodwill.

by TheAdviserMagazine
October 27, 2025
0

Wirestock Creators / Shutterstock.comAfter 35 years of thrift shopping and reselling, I’ve learned that large chains like Goodwill, Deseret Industries,...

edit post
AI drives huge productivity gains for big companies, small ones left behind

AI drives huge productivity gains for big companies, small ones left behind

by TheAdviserMagazine
October 27, 2025
0

Amazon Proteus robots demonstrate autonomous navigation using barcodes on the floor during the Delivering the Future event at the Amazon...

edit post
Give Up on These Overrated Retirement Tropes

Give Up on These Overrated Retirement Tropes

by TheAdviserMagazine
October 27, 2025
0

In This Article Remember the days when workers retired at 62 with a pension and lived comfortably for the rest...

edit post
Why West Coast Investors Are Turning to Midwestern Real Estate Notes

Why West Coast Investors Are Turning to Midwestern Real Estate Notes

by TheAdviserMagazine
October 27, 2025
0

In This Article This article is presented by Connect Invest. Prices on the West Coast are sky-high. San Francisco median...

edit post
Crypto Miners Are Pivoting to the New AI Goldmine

Crypto Miners Are Pivoting to the New AI Goldmine

by TheAdviserMagazine
October 27, 2025
0

Knowing when to pivot is what separates winning companies from the ones that history forgets. RCA built the first national...

Next Post
edit post
Hot Stocks: KW 34 / 2025 – Biotech-Aktien setzen ein Ausrufzeichen!

Hot Stocks: KW 34 / 2025 – Biotech-Aktien setzen ein Ausrufzeichen!

edit post
African Union endorses campaign to finally fix the maps that massively understate how big the continent really is

African Union endorses campaign to finally fix the maps that massively understate how big the continent really is

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Another Violent Outburst – Democrats Inciting Civil Unrest

Another Violent Outburst – Democrats Inciting Civil Unrest

October 24, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
CarTrade Tech Q2 profit more than doubles, stock surges 18% to all-time high

CarTrade Tech Q2 profit more than doubles, stock surges 18% to all-time high

0
edit post
10 Of The Right Retirement Stocks For Income Investors

10 Of The Right Retirement Stocks For Income Investors

0
edit post
Adam Smith Would Not Approve: The Evidence

Adam Smith Would Not Approve: The Evidence

0
edit post
F2Pool Co-Founder Refuses Bitcoin Anti-Spam Soft Fork

F2Pool Co-Founder Refuses Bitcoin Anti-Spam Soft Fork

0
edit post
10 Low-Cost Ways Boomers Can Boost Retirement Income Without New Skills

10 Low-Cost Ways Boomers Can Boost Retirement Income Without New Skills

0
edit post
Earnings Summary: A snapshot of Revvity’s (RVTY) Q3 2025 report

Earnings Summary: A snapshot of Revvity’s (RVTY) Q3 2025 report

0
edit post
F2Pool Co-Founder Refuses Bitcoin Anti-Spam Soft Fork

F2Pool Co-Founder Refuses Bitcoin Anti-Spam Soft Fork

October 28, 2025
edit post
Adam Smith Would Not Approve: The Evidence

Adam Smith Would Not Approve: The Evidence

October 28, 2025
edit post
Gen Zers are using AI to skip meetings, get promoted faster and win bigger salary hikes. But they don’t feel great about it

Gen Zers are using AI to skip meetings, get promoted faster and win bigger salary hikes. But they don’t feel great about it

October 28, 2025
edit post
Law firms call off mega merger

Law firms call off mega merger

October 28, 2025
edit post
Scott Galloway calls real estate ‘the most tax-advantaged’ investment you can make in the US

Scott Galloway calls real estate ‘the most tax-advantaged’ investment you can make in the US

October 28, 2025
edit post
10 Large-Cap Stocks That Could Outperform in a Market Primed for a Tech Rally

10 Large-Cap Stocks That Could Outperform in a Market Primed for a Tech Rally

October 28, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • F2Pool Co-Founder Refuses Bitcoin Anti-Spam Soft Fork
  • Adam Smith Would Not Approve: The Evidence
  • Gen Zers are using AI to skip meetings, get promoted faster and win bigger salary hikes. But they don’t feel great about it
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.